MedTrace Logo

IVI Aflibercept Before and After Phaco in DME.

NCT05731089 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-02-16

No results posted yet for this study

Summary

To study whether or not cataract surgery should be deferred until treating the co-existing diabetic macular edema (DME) using intravitreal (IVI) anti-vascular endothelial growth factor (anti-VEGF).

Conditions

Interventions

PROCEDURE

Phacoemulsification with IVI of aflibercept

IVI was either before or after cataract surgery

Sponsors & Collaborators

  • Al Hadi Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-01
Primary Completion
2022-08-01
Completion
2022-12-01

Countries

  • Kuwait

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05731089 on ClinicalTrials.gov